News & Updates

Show Multimedia Only

Drug-drug interactions rife among patients with haematologic malignancy

22 Dec 2025

A recent study has shown the prevalence of drug-drug interactions (DDIs) among hospitalized patients with haematologic malignancies, with the occurrence increasing alongside the number of medications administered.

Drug-drug interactions rife among patients with haematologic malignancy

22 Dec 2025

Insulin glargine improves glycaemic control in T2D patients in India

22 Dec 2025 by

Findings from the prospective PRIMARY-INDIA study presented at ATTD-Asia 2025 show clinically meaningful improvements in glycaemic control with insulin glargine in individuals with type 2 diabetes (T2D) in primary care settings, with a consistent safety profile.

Insulin glargine improves glycaemic control in T2D patients in India

22 Dec 2025

Insulin glargine/lixisenatide enhances T2DM control in real world

21 Dec 2025 by

Switching to insulin glargine/lixisenatide effectively lowers glucose levels in overweight adults with uncontrolled type 2 diabetes mellitus (T2DM), according to real-world data.

Insulin glargine/lixisenatide enhances T2DM control in real world

21 Dec 2025

DBT outclasses SSRI/M in reducing suicide among borderline personality disorder patients

21 Dec 2025

Six months of dialectical behaviour therapy (DBT) is more efficacious than 6 months of selective serotonin reuptake inhibitors with clinical management (SSRI/M) in the reduction of suicide-related events (SREs) and nonsuicidal self-injury (NSSI) behaviours in patients with borderline personality disorder, reports a study.

DBT outclasses SSRI/M in reducing suicide among borderline personality disorder patients

21 Dec 2025

Blood transfusions during major noncardiac surgeries reduced with tranexamic acid

20 Dec 2025 by

The use of the antifibrinolytic agent tranexamic acid during major noncardiac surgeries results in fewer red blood cell transfusions without an increase in venous thromboembolism, as shown in the phase IV TRACTION trial.

Blood transfusions during major noncardiac surgeries reduced with tranexamic acid

20 Dec 2025

Granisetron on par with palonosetron in preventing emesis in NSCLC patients

20 Dec 2025 by

Both granisetron and palonosetron are comparable in the prevention of acute and delayed emesis in patients with nonsmall cell lung cancer (NSCLC) receiving cisplatin based high emetogenic chemotherapy (HEC), a study has shown.

Granisetron on par with palonosetron in preventing emesis in NSCLC patients

20 Dec 2025

Corticosteroids, IVIG help reduce risk of aneurysm in children with MIS-C

19 Dec 2025

The use of corticosteroids, intravenous immunoglobulin (IVIG), and their combination appear to protect children with multisystem inflammatory syndrome (MIS-C) against aneurysm compared with no immunomodulatory treatment, suggests a study.

Corticosteroids, IVIG help reduce risk of aneurysm in children with MIS-C

19 Dec 2025

Once-daily osilodrostat restore cortisol rhythm in patients with Cushing syndrome

19 Dec 2025 by

Treatment with osilodrostat once daily is safe and effective in patients with biochemically controlled Cushing syndrome (CS), improving circadian cortisol rhythm, a study has shown.

Once-daily osilodrostat restore cortisol rhythm in patients with Cushing syndrome

19 Dec 2025

VAYHIT2 shows disease-modifying potential of ianalumab for ITP

19 Dec 2025 by

The primary analysis of the phase III VAYHIT2 trial shows the treatment potential of ianalumab when combined with standard-of-care eltrombopag in individuals with primary immune thrombocytopenia (ITP) requiring second-line (2L) treatment after failure of first-line (1L) corticosteroids.

VAYHIT2 shows disease-modifying potential of ianalumab for ITP

19 Dec 2025

Benralizumab reduces flare events in patients with hypereosinophilic syndrome

19 Dec 2025 by

Treatment with benralizumab is associated with a significantly reduced risk of flares in patients with hypereosinophilic syndrome (HES) compared with placebo, according to the NATRON study presented at ASH 2025.

Benralizumab reduces flare events in patients with hypereosinophilic syndrome

19 Dec 2025

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Drug-drug interactions rife among patients with haematologic malignancy

Drug-drug interactions rife among patients with haematologic malignancy

Insulin glargine improves glycaemic control in T2D patients in India

Insulin glargine improves glycaemic control in T2D patients in India

Insulin glargine/lixisenatide enhances T2DM control in real world

Insulin glargine/lixisenatide enhances T2DM control in real world

DBT outclasses SSRI/M in reducing suicide among borderline personality disorder patients

DBT outclasses SSRI/M in reducing suicide among borderline personality disorder patients

Blood transfusions during major noncardiac surgeries reduced with tranexamic acid

Blood transfusions during major noncardiac surgeries reduced with tranexamic acid

Granisetron on par with palonosetron in preventing emesis in NSCLC patients

Granisetron on par with palonosetron in preventing emesis in NSCLC patients

Corticosteroids, IVIG help reduce risk of aneurysm in children with MIS-C

Corticosteroids, IVIG help reduce risk of aneurysm in children with MIS-C

Once-daily osilodrostat restore cortisol rhythm in patients with Cushing syndrome

Once-daily osilodrostat restore cortisol rhythm in patients with Cushing syndrome

VAYHIT2 shows disease-modifying potential of ianalumab for ITP

VAYHIT2 shows disease-modifying potential of ianalumab for ITP

Benralizumab reduces flare events in patients with hypereosinophilic syndrome

Benralizumab reduces flare events in patients with hypereosinophilic syndrome